TMIGD2 in Bladder Cancer: A Bioinformatics and Experimental Approach to Understanding its Prognostic and Therapeutic Potential
This study demonstrates that TMIGD2 is downregulated in BLCA and correlates with adverse prognosis and immune regulation. Its potential as a prognostic biomarker and therapeutic target is underscored by its involvement in key pathways, immune infiltration, and drug sensitivity. Further research is essential to fully realize the clinical potential of TMIGD2 in the management of BLCA.
Authors
- Mingfeng Shen
- Zuomin Wang (ORCID: https://orcid.org/0009-0007-1856-3951)
- Yiwen Chen (ORCID: https://orcid.org/0009-0003-8102-7191)
- Zhihai Wu
- Dongbing Li
- Meiting Lao
- Wenxia Chen
- Wangdong Deng
Institutions
- Soochow University (CN)
- Longgang Central Hospital (CN)
Publication Details
- Journal
- Current Topics in Medicinal Chemistry
- Published
- 2026-01-15
- DOI
- https://doi.org/10.2174/0115680266414071251126071447
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00